Individuals with type 2 diabetes mellitus have increased cardiovascular disease risk compared with those without diabetes. Treatment of the residual risk, other than blood pressure and LDL-cholesterol control, remains important as the rate of diabetes increases worldwide. The accelerated atherosclerosis and cardiovascular disease in diabetes is likely to be multifactorial and therefore several therapeutic approaches can be considered. Results of mechanistic studies done in vitro and in vivo-animals and people-can provide important insights with the potential to improve clinical management decisions and outcomes. In this Review, we focus on three areas in which pathophysiological considerations could be particularly informative-ie, the roles of hyperglycaemia, diabetic dyslipidaemia (other than the control of LDL-cholesterol concentrations), and infl ammation (including that in adipose tissue) in the acceleration of vascular injury.
Introduction
Several mechanisms are likely to contribute to the accelerated atherosclerosis and increased cardiovascular disease risk noted in patients with type 2 diabetes mellitus. We focus on areas in which basic mechanistic studies have high relevance to present clinical controversies to understand and address cardiovascular disease risk in people with diabetes. We assess pathophysiological information linking hyperglycaemia, diabetic dyslipidaemia (other than the control of LDL cholesterol concentrations), and infl ammation to the accelerated vascular injury and cardiovascular disease risk in type 2 diabetes and discuss clinical considerations.
Hyperglycaemia and the vessel wall
Although a consistent association between glycaemic control and cardiovascular disease has been noted in epidemiological studies, 1 the eff ect of tight glycaemic control did not seem to reduce the cardiovascular risk in clinical trials. 2 Intensive glycaemic control in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) study 3 was stopped because of an increase in the number of cardiovascular deaths. A formal analysis of the results has not yet been reported. The ADVANCE (Action in Diabetes and Vascular Disease) study 4 will provide information about whether a good glycaemic control is of benefi t for cardiovascular disease. Results of basic studies in vitro, in animal models, and in patients with diabetes mellitus suggest several mechanisms by which hyperglycaemia might aff ect atherogenesis at the level of the artery wall (fi gure 1).
Hyperglycaemia can lead to vascular complications by several mechanisms. First, high glucose concentrations can activate nuclear factor κB (NF-κB), 5, 6 which in turn can increase the expression of various genes in the endothelial cells, monocyte-derived macro phages, and vascular smooth-muscle cells. Advanced glycation end-products (AGEs)-including protein cross-links, fl uorophors, and other low molecular-weight residuesare formed by sustained exposure of proteins and lipids to high concentrations of glucose, which can generate reactive oxygen species. Ligation of AGEs to specifi c cell-surface receptors can regulate gene expression in vessel-wall cells.
Glucose increases oxidative stress, which has several possible harmful eff ects on the artery wall-eg, auto-oxidation of glucose leads to the formation of several reactive oxygen species, such as the superoxide anion, which can promote LDL oxidation in vitro. 7 Indirect observational evidence suggests that lipoprotein oxidation might be increased in patients with type 2 diabetes 8 and is related to glycaemic control. 9 However, many of the studies relied on non-specifi c assays of oxidative stress. The absence of highly specifi c markers in collagen, 10 plasma, or urine from individuals with diabetes 11 does not support a generalised increase in oxidative stress in diabetes. Glycoxidation reactions are thought to contribute to macrovascular disease in diabetes by damaging tissues in the local microenvironment of the arterial wall. 11 The pathways leading to these reactions include the generation of superoxide in the mitochondria, NADPH generation by monocytederived macrophages, or a redox-sensitive mechanism that generates hydroxyl radicals. Accumulation of the products of hydroxyl radicals locally in arterial tissue of diabetic monkeys is consistent with a redox-sensitive mechanism.
glandin F2-an indicator of free radical production derived from arachidonic acid in cell membranes 13 -was increased in patients with diabetes compared with that in non-diabetic controls. 14 The concentrations of this prostaglandin were highest in patients with the greatest glycaemic variability. Moreover, this variability was a strong predictor of total free radical production, whereas postprandial blood glucose concentrations were not. Indeed, fl uctuations in blood glucose concentrations accelerated atherosclerosis in apolipoprotein-E-defi cient mice. 15 Further studies are needed to assess the importance of oxidative stress that results from glycaemic variability.
Glucose and the endothelium
An important initial event in the pathogenesis of atherosclerosis is the adhesion of circulating monocytes to arterial endothelial cells, followed by their transmigration into the subendothelial space along a chemotactic gradient (fi gure 1). Hyper glycaemia enhances monocyte adhesion to cultured aortic endothelial cells 16 by activation of NF-κB, 5, 6 which increases the expression of several infl ammatory genes, including adhesion molecules that promote monocyte adhesion to the endothelial cells (fi gure 1). 5 Expression of adhesion molecules might result from impaired nitric oxide production, since agents that increase the production of nitric oxide reduce the expression of adhesion molecules. 17 Glucose-mediated and AGE-mediated inhibition of nitric oxide production by endothelial cells is associated with impaired endothelial-dependent relaxation, [18] [19] [20] an early marker of vascular injury. In addition to substantial impairment of endothelium-dependent relaxation, diabetic mice show evidence of increased peroxynitrite generation, nitrotyrosine expression, and lipid peroxidation in the aortic tissues. 21 Hyperglycaemia and AGEs stimulate the production of superoxide by endothelial cells, partly by activation of NADPH oxidase, 6, 22 thereby providing a link between hyperglycaemia, AGEs, and oxidative stress.
Glucose and monocyte-derived macrophages
Both high glucose concentrations [23] [24] [25] and AGEs are associated with an increased state of activation of circulating monocytes in vitro and in vivo. Monocytes grown in the presence of high glucose concentrations or isolated from individuals with poorly controlled diabetes are in an activated and infl ammatory state, as shown, for example, by the increased expression of cytokines 23 interleukin 1β, and interleukin 6-and expression of CD36 and monocyte chemoattractant protein 1. 26 These infl ammatory changes are associated with induction of protein-kinase C, NF-κB activation, and increased release of superoxide, and all three could play a part in the oxidative stress that occurs in the presence of hyperglycaemia. 27 Monocytes entering the endothelial space in response to chemotactic factors, proliferate and diff erentiate into intimal macrophages, which accumulate in the artery wall in diabetes (fi gure 1). 27 Hyperglycaemia is not suffi cient to stimulate macrophage proliferation in lesions of atherosclerosis or in isolated murine macrophages; in combination with hyper lipidaemia, it stimulates macrophage proliferation by a pathway that might include glucose-dependent oxidation of LDL. 28 Arterial wall macrophages can accumulate lipid from modifi ed forms of LDL, which are taken up by scavenger receptors. The modifi cations include LDL that has become oxidised as a result of glucose-mediated oxidative stress 29 and AGE-modifi ed LDL. 30 Additionally, AGE-modifi ed albumin can inhibit the selective uptake of cholesteryl esters from HDL, 31 an essential step in reverse cholesterol transport. Thus, modifi cation of lipoproteins and other proteins resulting from an increased exposure to high glucose concentrations can change the delivery and removal of lipids from macrophages in a way that is likely to promote atherosclerosis.
Glucose and vascular smooth-muscle cells
High glucose concentrations can stimulate the proliferation of vascular smooth-muscle cells in vitro. 32 As atherosclerotic lesions progress, smooth-muscle cells migrate from the media to the intima, in which they proliferate, generate growth factors, and participate in the formation of a fi brous cap. Similar fi ndings were noted after exposure of cells to AGEs 33 and high insulin concentrations, 34 which often accompany hyperglycaemia in type 2 diabetes.
Vascular smooth-muscle cells generate several matrix molecules that are implicated in atherogenesis. Vascular proteoglycans bind atherogenic lipoproteins, leading to their retention in the subendothelial space. 35 At post-mortem examination, the expression of chondroitin sulphate and dermatan sulphate is increased and that of heparan sulphate proteoglycans is reduced in the atherosclerotic lesions of patients with diabetes compared with lesions from non-diabetic individuals. 36 The increase in chondroitin and dermatan sulphate proteoglycans might contribute to the increased atherosclerosis in patients with diabetes by increasing LDL retention in the artery wall. 35 In the rat 37 and pig 38 models, diabetes is associated with a loss of intimal elastin content and increased elastin fragmentation. Reduced intimal elastin content, whether through reduced production or increased breakdown, seems to promote atherosclerosis by mechanisms that are unclear. 38 Therefore, elastin fragmentation might be another mechanism by which hyperglycaemia increases atherosclerosis in diabetes. Collagen-synthesised by vascular smooth-muscle cells-accumulates in atherosclerosis. In the presence of hyperglycaemia, collagen undergoes increased nonenzymatic glycation that increases its ability to bind LDL, which could result in increased LDL retention in the vessel wall. This increased retention could promote vessel wall accumulation and infl ammation.
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Diabetic dyslipidaemia and the vessel wall
Diabetic dyslipidaemia is strongly related to athero sclerosis. Even though patients with type 2 diabetes might not have substantially increased concentrations of LDL-cholesterol compared with matched individuals without diabetes, a cornerstone of the management of cardiovascular disease risk in diabetes is the use of LDL-cholesterol-lowering drugs-ie, statins. These drugs generally reduce cardiovascular disease events by 25-50% 40, 41 but the excess residual cardiovascular disease risk remains for treated patients with diabetes compared with those without diabetes. 42 Some of this residual risk could be attributed to lipoprotein abnormalities in patients with type 2 diabetes that are not adequately managed by statin treatment. Type 2 diabetes is characterised by reduced HDL-cholesterol con centrations, increased triglyceride-rich lipoprotein concentrations, and abnormalities in the composition of HDL, LDL, and triglyceride-rich lipoprotein particles (panel).
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Triglyceride-rich lipoproteins
The triglyceride-rich lipoproteins-which can be increased in the fasting or postprandial state-in patients with type 2 diabetes are VLDL and metabolites of VLDL, and chylomicron remnants. The role of these lipoproteins in diabetic atherosclerosis remains controversial. Tri glyceride concentrations vary inversely with HDL-cholesterol concentrations, confounding interpretations related to increases in concentrations of triglyceride-rich lipoproteins to atherosclerosis. 45 Postprandial triglyceride concentrations might be a better predictor of cardiovascular disease events than fasting triglyceride concentrations, independently of HDL cholesterol concentrations. 46, 47 A proatherogenic eff ect of triglyceride-rich lipoproteins in the vessel wall is supported by substantial in-vitro evidence (fi gure 2). Triglyceride-rich lipoproteins enhance the proinfl ammatory phenotype of endothelial cells and macrophages and produce apoptosis in endothelial cells. 48 They increase expression of tumour necrosis factor α (TNFα) and adhesion receptors in macrophages, resulting in increased adherence of monocytes and monocyte-derived macrophages to endothelial cells. 49 Apolipo protein CIII-a component of triglyceride-rich lipo proteins and an inhibitor of lipo protein lipaseincreases adhesion of monocytic cells to endothelial cells. 50 Chylomicron remnants and triglyceride-rich lipoproteins produce lipid accumulation in macrophages. 51 Uptake of the lipid-rich VLDL particles is favoured by macrophages, promoting lipid accumulation. 52 Disruption of the VLDL receptor expression in macrophages reduces atherosclerosis in cholesterol-fed mice, whereas VLDL receptor expression in VLDL receptor-defi cient mice increases atherosclerosis. 53 Reduction in triglyceride-rich lipoprotein concentrations and hyperlipidaemia prevented disruption of atherosclerotic plaques in a mouse model of type 1 diabetes. 54 Increased concentrations of postprandial remnant lipoprotein particles have been proven to contribute to impaired arterial compliance. 55 The fatty-acid composition of chylomicron remnants aff ects their uptake and the induction of lipid accumulation in macrophages. 51 The ability of triglyceride-rich lipoprotein particles to induce an infl ammatory phenotype in macrophages might be enhanced by lipolytic release of fatty acids from VLDL. 51, 56 Increased concentrations of free fatty acids are another component of diabetic dyslipidaemia and accompany increased triglyceride concentrations. Fatty acids can directly lead to changes in the composition of the extracellular matrix produced by arterial smooth-muscle cells in a manner that favours increased immobilisation and retention of lipoproteins. 57 Excess free-fatty-acid delivery to peripheral tissues can worsen insulin resistance and might play a part in activation of the infl ammatory processes through activation of toll-like receptors. 58 Free fatty acids are proven to impair endothelium-dependent vasodilation 59 and disrupt the function of cellular sterol transporters that are important for reverse cholesterol transport. 60 However, data suggest that in some circumstances physiological lipolysis of triglyceride-rich lipoproteins might have benefi cial anti-infl ammatory eff ects. In some model systems, the lipolytic release of fatty acids can provide a ligand for nuclear hormone receptors-such as the peroxisome-proliferator-activated receptor (PPAR) γ-which are implicated in the inhibition of infl ammation. 61, 62 Taken together, these results suggest that inappropriate generation or handling of fatty acids, or both, might represent a fundamental abnormality in diabetes, leading to accelerated atherosclerosis.
LDL
Patients with type 2 diabetes might not have substantially higher concentrations of LDL cholesterol than matched individuals without diabetes, but for any LDL-cholesterol concentration, those with diabetes generally have an increase in LDL particles 43, 45 because small, dense lipid-poor LDL particles accumulate in the circulation. Each LDL particle contains one apolipoprotein-B molecule and therefore patients with type 2 diabetes will also have a parallel increase in concentrations of apolipoprotein B. An increased number of LDL particles, measured directly or indirectly by concentrations of apolipoprotein B, might contribute to atherogenesis and cardiovascular disease risk. [63] [64] [65] An increase in the number of LDL particles in diabetes can be treated by statins. However, a separate issue is whether or not small, dense LDL particles are inherently more atherogenic on a per-particle basis than the larger buoyant particles. An increased atherogenicity of small, dense LDL particles is supported by results of in-vitro studies, showing that small LDL particles rapidly enter the arterial wall and can be toxic to endothelial cells, cause greater production of procoagulant factors, be oxidised more readily, and be more readily immobilised by proteoglycans present in the arterial wall than can the large buoyant particles. 66 The small particles do not bind very well to the LDL receptor, which might lead to impaired clearance by the liver. 66 How these in-vitro results translate to the in-vivo milieu, however, remains unclear. A satisfactory in-vivo model for testing atherogenicity of small, dense LDL particles on a per-particle basis compared with large particles is needed. In non-human primates fed fat-modifi ed diets, LDL-particle size was not independently atherogenic. 67 Results from studies of healthy individuals 68 and those with coronary heart disease 69 showed that both large and small LDL particles are related to atherosclerosis and cardiovascular disease.
HDL
Individuals with type 2 diabetes mellitus have reduced HDL cholesterol and circulating apolipoprotein AI-the major apolipoprotein in HDL cholesterol. 70 Abnormalities in the size and composition of the HDL particle have also been noted in diabetic patients. 43, 45, 71, 72 HDL and apolipoprotein AI remove excess cholesterol from atherosclerotic plaque cells, and their reduced concentrations in diabetes would be expected to have a detrimental eff ect on cholesterol content in vessel walls (fi gure 2). The cell type of most interest is the monocytederived macrophage because cholesterol-ester-engorged macrophages (ie, foam cells) are hallmarks of the atherosclerotic plaque. Removal of cholesterol from macrophages is thought to be an important fi rst step in the process of reverse cholesterol transport, and might be important for the prevention of progression and for regression of atherosclerotic plaques. 73 The HDL particle and its apolipoprotein-AI component might act through distinct cellular sterol transporters for removal of cholesterol from cells. The HDL particle seems to rely mainly on the ATP-binding cassette transporter G1 to facilitate sterol effl ux, and expression of this transporter in cells can be inhibited by exposure to glycosylated proteins. 74 Additionally, glycation of apolipoprotein AI, which acts mainly through the ATP-binding cassette transporter A1, sup presses its ability to remove cholesterol from cells. 75 HDL has anti-infl ammatory and antioxidant properties in cells of the vessel wall. 76, 77 Monocyte-derived macro phages isolated from individuals with low HDL cholesterol concentrations manifest a proinfl ammatory phenotype. 78 In addition to changes in HDL-cholesterol and apolipoprotein-AI concentrations, patients with type 2 diabetes have changes in HDL composition. HDL is perhaps the most heterogeneous and complex of all lipoprotein particles, and changes in its composition might aff ect HDL atheroprotective properties (fi gure 2). 79 In isolated cells, HDL particles of diff erent sizes and composition show diff erent abilities to remove cholesterol from cells. 80 Changes in the content of many proteins associated with HDL, for example paroxonase (opposes oxidation of lipoprotein lipid), 81 might change its atheroprotective properties. 82 Compositional abnormalities of HDL isolated from patients with type 2 diabetes have been linked to impaired antiatherogenic properties. 71 Cholesterol-ester transfer protein inhibition with torcetrapib did not protect against cardio vascular disease events, underscoring the notion that HDL-particle composition might be more important than HDL-cholesterol concentrations for reduction of cardiovascular disease risk. 83 Mice without apolipoprotein AI and with very low HDL cholesterol concentrations have increased rates of atherosclerosis because of both reduced cholesterol transport and increased infl ammation. 84 Conversely, increased expression of apolipoprotein AI with high HDL-cholesterol concentrations reduces the amount of atherosclerosis in the apolipoprotein-E−/− mouse-a model of accelerated and progressive atherosclerosis. 85 An increase in HDL-cholesterol concentrations in patients with type 2 diabetes has been linked to reduced carotid atherosclerosis. 86, 87 HDL has been proven to improve mobilisation and function of endothelial precursor cells 88 and to protect the myocardium from ischaemia and reperfusion injury. 89 
Glycaemia versus hyperlipidaemia in pathogenesis of atherosclerosis
The roles of hyperglycaemia and hyperlipidaemia in atherogenesis have been diffi cult to separate in animal models of diabetes. Hyperlipidaemia is usually exacerbated by the onset of hyperglycaemia-eg, in mouse models of LDL-receptor defi ciency and apolipoprotein-E defi ciency-thereby confounding the eff ect of hyperglycaemia. However, in two animal models, hyperglycaemia seems to have an independent role. 90, 91 First, fat-fed diabetic pigs had more atherosclerosis than equally dyslipidaemic fat-fed animals without diabetes. 90 Second, consumption of a cholesterol-free diet by LDL-receptor-defi cient mice with a novel form of diabetes induced by a β-cell-directed viral antigen resulted in hyperglycaemia without changes in lipids and lipoproteins. 91 Hyperglycaemia was associated with lesion initiation. Addition of increasing amounts of dietary cholesterol led to dyslipidaemia, which was the major factor in atherosclerosis progression, independent of hyper glycaemia.
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Chronic subclinical infl ammation and the vessel wall
Evidence ranging from pathological studies in people to in-vivo mouse models has established the role of infl ammatory cells (such as macrophages and T lymphocytes) and infl ammatory mechanisms (such as cytokine release) in the pathogenesis of atherosclerosis. 92 Because type 2 diabetes and atherosclerosis are chronic conditions that take decades to arise, the cause and eff ect are diffi cult to discern (fi gure 3). Infl ammation is implicated in the pathogenesis of type 2 diabetes and atherosclerosis. 93, 94 Since diabetes promotes atherosclerosis and increases cardiovascular events, a distinction might exist between infl ammation that fosters diabetes and infl ammation that arises after the type 2 diabetes and promotes atherosclerosis directly (fi gure 3). Most of the infl ammatory mechanisms discussed also seem to be implicated in the atherosclerosis seen in prediabetic and non-diabetic states. Although the evidence implicating infl ammation in atherosclerosis and type 2 diabetes is wide-ranging, a specifi c mechanism or an integrated framework has not been identifi ed to explain precisely why patients with diabetes are at increased risk of infl ammation or atherosclerosis.
Mechanisms of infl ammation in diabetic atherosclerosis
The endothelium-as the cellular interface between the circulation and hyperglycaemia and dyslipidaemia that characterise type 2 diabetes mellitus-responds to hyperglycaemia and dyslipidaemia by showing an infl ammatory response. 95 Most of the responses induced in atherosclerosis are common to both diabetic and non-diabetic atherosclerosis. Classic proatherosclerotic endothelial responses-adhesion-molecule expression, secretion of chemokines, and coagulation proteins (plasminogen activator inhibitor 1, total plasminogen activator, and tissue factor), release of vasoactive mediators (endothelial nitric oxide and bradykinin)-are induced or regulated by infl ammatory stimuli in diabetes models in vitro or in vivo, or both. 96, 97 Lymphocytes provide crucial proinfl ammatory signals to monocyte-derived macrophages and vascular smooth-muscle cells, and are activated by metabolic stimuli. [98] [99] [100] Macrophages directly respond to the common abnormalities in type 2 diabetes-eg, glucose, free fatty acids, and hypertriglyceridaemia-by augmentation of the infl ammatory responses. 92, 101 Several stimuli and cellular pathways are implicated in the eff ects of macrophages (fi gure 4), including increased foam-cell formation, release of matrix metalloproteinases, and secretion of growth factors and cytokines. 94, 102 These eff ects emphasise the important link between insulin resistance, infl ammation, and atherosclerosis. When bone marrow from insulin-receptor-defi cient mice was transplanted into LDL-receptor-defi cient mice, lesions of increased complexity were noted. 103 Macrophage-specifi c defi ciency of the nuclear receptor PPARγ in mice worsens insulin resistance, 104, 105 suggesting that the presence of this ligand-activated transcription factor in macrophages regulates insulin sensitivity, which could be related to PPARγ-mediated inhibition of infl ammation. 106 Similar issues apply to retinoid signalling through the retinoid-X receptor, the essential partner of PPARγ and many other nuclear receptors. 102, 107 The available data suggests cellular responses to injury, infl ammation, and metabolism might converge on control points that are important in atherosclerosis. A central regulator of infl ammation is NF-κB, 108 a transcriptional complex activated by various stimuli, including cytokines, oxidised LDL, lipopolysaccharide, and oxidative stress (fi gure 4). 94 NF-κB is reported to regulate LDL oxidative modifi cation, chemokine and cytokine expression, macrophage growth and diff erentiation, apoptosis, and vascular smooth-muscle cell proliferation. NF-κB, its regulatory proteins (eg, inhibitor κB), and distal targets (eg, c-Jun N-terminal kinase) have all been strongly implicated in insulin sensitivity and in atherosclerosis (fi gure 4). 94, 102, 109, 110 NF-κB might have a role in the common pathway, linking many inputs that are activated in type 2 diabetes mellitus to atherosclerotic responses. It is activated by factors commonly abnormal in type 2 dis ease mellitus, including fatty acids, glucose, AGE pathways, and some toll like receptors-a family of pattern recognition receptors expressed in various infl ammatory cells.
111 Several NF-κB-regulated targets are implicated in diabetic atherosclerosis, including TNFα, which increases insulin resistance, toll-like receptors, and resistin. In mice, inhibition of NF-κB activation can improve insulin sensitivity and reduce atherosclerosis; this inhibition (eg, by high-dose salicylates) is also being investigated in people. 94 PPARγ's anti-infl ammatory and anti atherosclerotic eff ects in vitro and in mice might work through NF-κB inhibition (fi gure 4). 106 Several mechanistic pathways have been proposed for how glucose brings about cellular injury and subsequent infl ammation. Cells that do not have the ability to counter the increase in intracellular glucose concentrations might activate pathways of cellular injury and infl ammation. 112 These mechanisms include activation of protein-kinase C, formation of polyols, which promotes intracellular oxidative stress, and increased hexosamine activation, with subsequent increases in reactive oxidant species and mitochondrial stress. [113] [114] [115] Although much of this evidence was linked to diabetic microvascular disease, increased fl ux of free fatty acids into the endothelium might cause macro vascular disease through similar pathways, inducing infl ammation.
All secretory and membrane proteins, many nutrients, and many pathogens pass through the endoplasmic reticulum. Several lines of study implicate endoplasmic reticulum stress in the promotion of infl ammation. 116 Hypoxia, hyperglycaemia, and increased fatty-acid concentrations can all induce endoplasmic reticulum stress and a specifi c cellular process known as the unfolded protein response, 117 which is a homoeostatic mechanism that restores normal endoplasmic reticulum function. Endoplasmic reticulum stress, present in the liver and adipose tissue, can activate pathways leading to oxidation and infl ammation and has been implicated in both diabetes and atherosclerosis. 118 
Adipose tissue infl ammation
Adipose tissue is a biologically active endocrine and paracrine organ. The theory that it could be involved in diabetic atherosclerosis has many implications for the intersection of infl ammation, atherosclerosis, and type 2 diabetes mellitus, especially since clinical data suggests that adiposity is a core defect in the metabolic abnormalities that arise before and during diabetes. 96 Infl ammation in adipose tissue might contribute to abnormal metabolism and atherosclerosis in type 2 diabetes.
Oxidative stress, endoplasmic reticulum stress, and NF-κB activation pathways also operate in adipocytes. 96, 102 Oxidative stress and infl ammation in adipose tissue can be exacerbated by hyperglycaemia. 119 Fatty acids released from adipose tissue might signal to macrophages through pathways that involve toll-like receptors, leading to NF-κB activation. Many of the same pathways involved in the recruitment of leucocytes to the arterial wall also recruit infl ammatory cells to fat, including monocyte chemoattractant protein 1. 120 Indeed, mice defi cient in C-C chemokine receptor-2-ie, the receptor for monocyte chemoattractant protein 1-are aff orded some degree of protection from diet-induced insulin resistance and induction of infl ammation. 121 Excess lipid accumulation in other tissues-eg, skeletal muscle and the livermight modulate infl ammation, contributing to insulin resistance and atherosclerosis. 122, 123 Increased concentrations of infl ammatory cytokines released from visceral fat in diabetes and obesity can act directly on the liver to increase the circulating concentrations of proinfl ammatory molecules such as C-reactive protein and serum amyloid A. 124 C-reactive protein might directly amplify injury at the vessel wall and serum amyloid A unfavourably modifi es the composition and function of HDL. The expression of adipose tissue apolipoproteins, which aff ect adipocyte lipid metabolism, is modifi ed by infl ammatory cytokines. 125, 126 Several adipocyte-specifi c mediators have been implicated in the infl ammation contributing to insulin resistance and atherosclerosis. Leptin is an adipocyte-specifi c signal that seems to exert systemic proinfl ammatory eff ects. 127 It produces proinfl ammatory changes in endothelial cells and macro phages, and its administration to apolipoprotein-E-defi cient mice promotes atherosclerosis. 124 Adiponectin, which circulates in the plasma in various multimeric forms, restricts infl ammatory and atherosclerotic responses. 128, 129 Adiponectin concentrations are reduced in obesity and diabetes. 124, 128 and the treatment of apolipo protein-E-defi cient mice with an adiponectinexpressing adenovirus has proven to reduce athero sclerotic plaque formation. 124 Adiponectin is present at higher concentrations in the subcutaneous fat adipocytes than in visceral fat adipocytes, one of many examples that suggest both depot-specifi c diff erences in fat and increased pathogenicity from visceral fat.
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Conclusions
Data from in-vitro and animal model studies support the argument that the absence of intensive glycaemic control in the ACCORD trial 3 should not eliminate hyperglycaemia as an important therapeutic target for reduction of cardiovascular disease in diabetes; the absence of eff ect might relate to an unfavourable benefi t to risk ratio of the presently available glucose-lowering treatments in the patients recruited for that trial. In the ACCORD trial, 3 the elderly at risk patients might have had increased susceptibility to the adverse eff ects of hypoglycaemia, offtarget drug eff ects, or the risk imposed by ectopic fat deposition that usually accompany intensifi cation of glucose-lowering treat ments. 130 The lipid arm of the ACCORD trial 131 will provide information about the value of adding a fi brate (which can increase HDL concentrations) to statin treatment in patients with type 2 diabetes. Information obtained from animal models about the complexity of HDL metabolism and HDL's potent atheroprotective eff ect argues that, despite the apparent failure of torcetrapib, other mechanisms for increasing HDL-cholesterol concentrations warrant assessment. Although therapeutic interventions in people can never be as targeted or specifi c as the experimental manipulations achievable in isolated cells or in animal models, pathophysiological and mechanistic information from these models provide key insights for the design and assessment of new treatment options to reduce cardiovascular disease in type 2 diabetes.
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